Source 1primary paper2025MED
Toolkit/self-complementary AAV genomes
self-complementary AAV genomes
Also known as: scAAV, self-complementary genomes
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Usefulness & Problems
Why this is useful
Self-complementary genomes are described as an AAV engineering innovation used in targeted gene delivery systems for hereditary skeletal myopathies.; AAV engineering for muscle-targeted gene delivery
Source:
Self-complementary genomes are described as an AAV engineering innovation used in targeted gene delivery systems for hereditary skeletal myopathies.
Source:
AAV engineering for muscle-targeted gene delivery
Problem solved
The abstract groups them with other innovations that enhance muscle tropism while mitigating immunogenicity and off-target effects.; improving engineered AAV performance for muscle-targeted delivery
Source:
The abstract groups them with other innovations that enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
improving engineered AAV performance for muscle-targeted delivery
Problem links
improving engineered AAV performance for muscle-targeted delivery
LiteratureThe abstract groups them with other innovations that enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
The abstract groups them with other innovations that enhance muscle tropism while mitigating immunogenicity and off-target effects.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
No mechanism tags yet.
Target processes
No target processes tagged yet.
Input: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
requires use within AAV vector genome design
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
AAV-based therapies such as Elevidys for DMD and Zolgensma for SMA demonstrate functional improvements, although immune responses and hepatotoxicity remain concerns.
Clinically, AAV-based therapies (e.g., Elevidys® for DMD, Zolgensma® for SMA) demonstrate functional improvements, though immune responses and hepatotoxicity remain concerns.
Non-viral vectors including liposomes, polymers, and exosomes offer advantages in cargo capacity, biocompatibility, and scalable production, but they face challenges in transduction efficiency and endosomal escape.
Non-viral vectors (liposomes, polymers, exosomes) offer advantages in cargo capacity (delivering full-length dystrophin), biocompatibility, and scalable production but face challenges in transduction efficiency and endosomal escape.
AAV vectors dominate clinical applications for gene therapy in hereditary skeletal myopathies because they efficiently transduce post-mitotic myofibers and support sustained transgene expression.
Adeno-associated virus (AAV) vectors dominate clinical applications due to their efficient transduction of post-mitotic myofibers and sustained transgene expression.
AAV engineering innovations including capsid modification, self-complementary genomes, and tissue-specific promoters such as MHCK7 enhance muscle tropism while mitigating immunogenicity and off-target effects.
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Future targeted gene delivery strategies for muscular disorders emphasize AI-driven vector design, AAV-exosome hybrid systems, and standardized manufacturing to pursue single-dose lifelong therapeutic benefit.
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Approval Evidence
1 source1 linked approval claimfirst-pass slug self-complementary-aav-genomes
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
engineering effectsupports
AAV engineering innovations including capsid modification, self-complementary genomes, and tissue-specific promoters such as MHCK7 enhance muscle tropism while mitigating immunogenicity and off-target effects.
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
Comparisons
Source-backed strengths
presented as an AAV engineering innovation
Source:
presented as an AAV engineering innovation
Compared with bacterial degrons
self-complementary AAV genomes and bacterial degrons address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
self-complementary AAV genomes and Pyr-NHS-functionalised 3D graphene foam electrode biosensor address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
Compared with rM3Ds
self-complementary AAV genomes and rM3Ds address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
Ranked Citations
- 1.